MA65277B1 - Inhibiteurs de l'inflammasome nlrp3 - Google Patents
Inhibiteurs de l'inflammasome nlrp3Info
- Publication number
- MA65277B1 MA65277B1 MA65277A MA65277A MA65277B1 MA 65277 B1 MA65277 B1 MA 65277B1 MA 65277 A MA65277 A MA 65277A MA 65277 A MA65277 A MA 65277A MA 65277 B1 MA65277 B1 MA 65277B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- nlrp3 inflammasome
- useful
- inflammasome inhibitors
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne d'une manière générale des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, R1, R2A, R2B, R2C, R2D, W, X, Y et Z ayant les significations définies dans la description. De tels composés sont utiles pour inhiber l'activité de l'inflammasome NLRP3 et peuvent être utiles en tant qu'agents thérapeutiques. L'invention concerne également l'utilisation de tels composés pour traiter ou prévenir des maladies et des affections dans lesquelles l'inflammasome NLRP3 est impliqué. L'invention concerne en outre des compositions comprenant de tels composés.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217970P | 2021-07-02 | 2021-07-02 | |
| PCT/EP2022/068292 WO2023275366A1 (fr) | 2021-07-02 | 2022-07-01 | Inhibiteurs de l'inflammasome nlrp3 |
| EP22744149.0A EP4363406B1 (fr) | 2021-07-02 | 2022-07-01 | Inhibiteurs de l'inflammasome nlrp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA65277B1 true MA65277B1 (fr) | 2025-12-31 |
Family
ID=82611090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA65277A MA65277B1 (fr) | 2021-07-02 | 2022-07-01 | Inhibiteurs de l'inflammasome nlrp3 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11970463B2 (fr) |
| EP (2) | EP4628490A3 (fr) |
| JP (1) | JP2024523623A (fr) |
| KR (1) | KR20240031343A (fr) |
| CN (1) | CN117580826A (fr) |
| AR (1) | AR126351A1 (fr) |
| AU (2) | AU2022304254B2 (fr) |
| BR (1) | BR112023026976A2 (fr) |
| CA (1) | CA3224513A1 (fr) |
| CL (1) | CL2023003939A1 (fr) |
| CO (1) | CO2024000565A2 (fr) |
| CR (1) | CR20240038A (fr) |
| DK (1) | DK4363406T3 (fr) |
| DO (1) | DOP2024000002A (fr) |
| EC (1) | ECSP24008862A (fr) |
| ES (1) | ES3054790T3 (fr) |
| FI (1) | FI4363406T3 (fr) |
| HR (1) | HRP20251513T1 (fr) |
| IL (1) | IL309680A (fr) |
| LT (1) | LT4363406T (fr) |
| MA (1) | MA65277B1 (fr) |
| MX (1) | MX2024000234A (fr) |
| PE (1) | PE20250122A1 (fr) |
| PL (1) | PL4363406T3 (fr) |
| PT (1) | PT4363406T (fr) |
| RS (1) | RS67463B1 (fr) |
| SI (1) | SI4363406T1 (fr) |
| SM (1) | SMT202500441T1 (fr) |
| TW (1) | TW202321201A (fr) |
| UY (1) | UY39839A (fr) |
| WO (1) | WO2023275366A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| IL307201A (en) | 2021-06-04 | 2023-11-01 | Hoffmann La Roche | Triazine derivatives and their use in cancer treatment. |
| IL310264A (en) * | 2021-07-21 | 2024-03-01 | Nico Therapeutics Inc | Annulated pyridazine compound |
| AU2022334474A1 (en) | 2021-08-25 | 2024-03-14 | Ptc Therapeutics, Inc. | Inhibitors of nlrp3 |
| AU2022355409B2 (en) * | 2021-09-30 | 2025-10-16 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| WO2023066377A1 (fr) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | Composé contenant de l'azote, son procédé de préparation et son application |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| IL321783A (en) * | 2022-12-28 | 2025-08-01 | Astrazeneca Ab | Crystalline forms of NLRP3 inflammasome inhibitors, chemical processes and chemical compounds |
| EP4644380A1 (fr) | 2022-12-28 | 2025-11-05 | Changchun Genescience Pharmaceutical Co., Ltd. | Composé inhibiteur de pyridazine nlrp3, composition pharmaceutique, procédé de préparation correspondant et utilisation associée |
| TW202502344A (zh) | 2023-06-02 | 2025-01-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環 |
| WO2025111267A1 (fr) * | 2023-11-20 | 2025-05-30 | Ventus Therapeutics U.S., Inc. | Formes de base libre solides de 5-chloro-2-(4-((2-hydroxy-2-méthylpropyl)amino)pyrido[3,4-d[pyridazin-1-yl)phénol pour inhiber nlrp3 et leurs utilisations |
| WO2025153532A1 (fr) | 2024-01-16 | 2025-07-24 | NodThera Limited | Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1 |
| WO2026002229A1 (fr) * | 2024-06-28 | 2026-01-02 | 长春金赛药业有限责任公司 | Composé inhibiteur de nlrp3, son procédé de préparation et son utilisation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338591B2 (en) | 2004-05-08 | 2012-12-25 | Novartis International Pharmaceutical Ltd. | 3-aryl-5,6-disubstituted pyridazines |
| BR112020008981A2 (pt) * | 2017-11-09 | 2020-11-17 | Inflazome Limited | novos compostos de sulfonamida carboxamida |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| US20230107277A1 (en) | 2020-03-27 | 2023-04-06 | Astellas Pharma Inc. | Substituted pyridazine compound |
| US20240391895A1 (en) * | 2020-12-25 | 2024-11-28 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyridazine-containing compound and medicinal use thereof |
| CN116867769A (zh) | 2021-02-08 | 2023-10-10 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| JP2024529839A (ja) | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
-
2022
- 2022-07-01 AR ARP220101723A patent/AR126351A1/es unknown
- 2022-07-01 WO PCT/EP2022/068292 patent/WO2023275366A1/fr not_active Ceased
- 2022-07-01 MA MA65277A patent/MA65277B1/fr unknown
- 2022-07-01 US US17/810,367 patent/US11970463B2/en active Active
- 2022-07-01 ES ES22744149T patent/ES3054790T3/es active Active
- 2022-07-01 JP JP2023580488A patent/JP2024523623A/ja active Pending
- 2022-07-01 FI FIEP22744149.0T patent/FI4363406T3/fi active
- 2022-07-01 EP EP25190541.0A patent/EP4628490A3/fr active Pending
- 2022-07-01 IL IL309680A patent/IL309680A/en unknown
- 2022-07-01 BR BR112023026976A patent/BR112023026976A2/pt unknown
- 2022-07-01 RS RS20251208A patent/RS67463B1/sr unknown
- 2022-07-01 MX MX2024000234A patent/MX2024000234A/es unknown
- 2022-07-01 PT PT227441490T patent/PT4363406T/pt unknown
- 2022-07-01 DK DK22744149.0T patent/DK4363406T3/da active
- 2022-07-01 HR HRP20251513TT patent/HRP20251513T1/hr unknown
- 2022-07-01 CA CA3224513A patent/CA3224513A1/fr active Pending
- 2022-07-01 AU AU2022304254A patent/AU2022304254B2/en active Active
- 2022-07-01 KR KR1020247003701A patent/KR20240031343A/ko active Pending
- 2022-07-01 PL PL22744149.0T patent/PL4363406T3/pl unknown
- 2022-07-01 CN CN202280045960.2A patent/CN117580826A/zh active Pending
- 2022-07-01 SM SM20250441T patent/SMT202500441T1/it unknown
- 2022-07-01 CR CR20240038A patent/CR20240038A/es unknown
- 2022-07-01 LT LTEPPCT/EP2022/068292T patent/LT4363406T/lt unknown
- 2022-07-01 SI SI202230216T patent/SI4363406T1/sl unknown
- 2022-07-01 TW TW111124687A patent/TW202321201A/zh unknown
- 2022-07-01 PE PE2023003486A patent/PE20250122A1/es unknown
- 2022-07-01 EP EP22744149.0A patent/EP4363406B1/fr active Active
- 2022-07-04 UY UY0001039839A patent/UY39839A/es unknown
-
2023
- 2023-12-28 CL CL2023003939A patent/CL2023003939A1/es unknown
-
2024
- 2024-01-02 DO DO2024000002A patent/DOP2024000002A/es unknown
- 2024-01-24 CO CONC2024/0000565A patent/CO2024000565A2/es unknown
- 2024-02-02 EC ECSENADI20248862A patent/ECSP24008862A/es unknown
- 2024-03-21 US US18/612,849 patent/US12503445B2/en active Active
-
2025
- 2025-09-02 AU AU2025223957A patent/AU2025223957A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA65277B1 (fr) | Inhibiteurs de l'inflammasome nlrp3 | |
| MA27957A1 (fr) | Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| NO20071042L (no) | 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| EP2597953A4 (fr) | Méthode de traitement de maladies ophtalmiques à l'aide de composés d'inhibiteurs de kinase sous forme de promédicaments | |
| TNSN04151A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 | |
| MA30208B1 (fr) | Derives de pyrimidine utilises en tant qu'inhibiteurs de kinase pi -3 | |
| MA27808A1 (fr) | Derives de quinoleine utilises en tant qu'inhibiteurs de la phosphodiesterase | |
| ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
| EA200000871A1 (ru) | Ингибиторы фосфолипазных ферментов | |
| MA30313B1 (fr) | Amines secondaires en tant qu'inhibiteurs de la renine | |
| ZA200408283B (en) | 7-aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardivascular or rental diseases | |
| MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA27491A1 (fr) | Derives de phenyl-ou heteroarylamino-alcanes comme antagonistes ou recepteur ip | |
| MA30296B1 (fr) | Nouvelles amines | |
| MA29267B1 (fr) | Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension. | |
| ATE453395T1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
| MA30292B1 (fr) | Amines primaires comme inhibiteurs de la renine | |
| JP4589122B2 (ja) | ホスホジエステラーゼ１０ａ阻害剤 | |
| JP2020007262A (ja) | 皮膚外用組成物 | |
| NZ237451A (en) | The use of 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)indole-1-carboxamide in the preparation of a pharmaceutical composition |